Fluminorex
Clinical data
ATC code
  • none
Identifiers
  • (RS)-5-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1,3-oxazol-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC10H9F3N2O
Molar mass230.190 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • FC(F)(F)c1ccc(cc1)C2O\C(=N/C2)N
  • InChI=1S/C10H9F3N2O/c11-10(12,13)7-3-1-6(2-4-7)8-5-15-9(14)16-8/h1-4,8H,5H2,(H2,14,15) checkY
  • Key:NMGYDYBWRZHLHR-UHFFFAOYSA-N checkY
  (verify)

Fluminorex is a centrally acting sympathomimetic which is related to other drugs such as aminorex and pemoline. It was developed as an appetite suppressant by McNeil Laboratories in the 1950s.[1][2]

Synthesis

Synthesis:[3] Patent (Ex XV):[4]

2-amino-1-[4-(trifluoromethyl)phenyl]ethanol [776-02-3] (1) cyanogen bromide [506-68-3] (2)

See also

References

  1. ^ US Patent 3278382 - 2-amino-5-aryloxazoline compositions and methods of using same
  2. ^ Maier J, Mayer FP, Brandt SD, Sitte HH (October 2018). "DARK Classics in Chemical Neuroscience: Aminorex Analogues". ACS Chemical Neuroscience. 9 (10): 2484–2502. doi:10.1021/acschemneuro.8b00415. PMC 6287711. PMID 30269490.
  3. ^ Poos, G. I., Carson, J. R., Rosenau, J. D., Roszkowski, A. P., Kelley, N. M., McGowin, J. (May 1963). "2-amino-5-Aryl-2-oxazolines. Potent New Anorectic Agents". Journal of Medicinal Chemistry. 6 (3): 266–272. doi:10.1021/jm00339a011. PMID 14185981.
  4. ^ Poos George Ireland, U.S. patent 3,278,382 (1966 to Janssen Pharmaceuticals Inc).


Categories